scorecardresearch
Add as a preferred source on Google
Friday, August 14, 2026
Support Our Journalism
HomeIndiaOdisha-based start-up tests drug manufacturing in near-space mission

Odisha-based start-up tests drug manufacturing in near-space mission

Follow Us :
Text Size:

New Delhi, Aug 14 (PTI) An Odisha-based space start-up successfully demonstrated drug crystallisation processes on a satellite prototype in a near-space mission, taking it a step further towards its goal of pharmaceutical manufacturing in low Earth orbit.

The orbital-class satellite prototype of Serendipity Space tested core technologies, including advanced heatshield systems, avionics and its autonomous pharmaceutical factory, Alchemy, company founder and CEO Antariksh Parichha said in a statement.

“The system operated continuously in harsh space conditions, successfully executing drug crystallisation processes and preserving crystal integrity through a controlled return, touchdown and recovery,” he said.

Parichha drew inspiration from an easier-to-inject version of the cancer drug Keytruda that was developed in the microgravity lab on the International Space Station by Merck in collaboration with NASA.

Serendipity Space’s mission carried commercial monoclonal antibody therapeutics and small molecules, each underpinning multi-billion-dollar markets, alongside additional proteins for drug discovery.

The launch was conducted using a stratospheric balloon launch platform leveraging the decades-long expertise of scientists at the Tata Institute of Fundamental Research (TIFR) Balloon Facility, Hyderabad.

The Bhubaneswar-based start-up is building satellites that can autonomously manufacture pharmaceuticals in space and bring them back to Earth, targeting a critical bottleneck in drug development.

“On Earth, gravity disrupts crystallisation, leading to defects that reduce drug solubility, stability and effectiveness. In microgravity, these constraints disappear, enabling the formation of superior crystal structures without altering the underlying chemistry of the drug,” Parichha said.

He said many existing drugs suffer from poor bioavailability due to suboptimal crystal forms.

In parallel, protein-based therapies like monoclonal antibodies often require long IV infusions because high-concentration formulations become unstable while being made under gravity.

Microgravity can enable uniform, stable formulations that could shift these treatments to simple at-home injections.

Serendipity Space was co-founded by Parichha, Jivitesh Debata and Dr Monica Ekal, combining their expertise in physics, engineering and space operations. PTI SKU DIV DIV

This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.

Subscribe to our channels on YouTube, Telegram & WhatsApp

Support Our Journalism

India needs fair, non-hyphenated and questioning journalism, packed with on-ground reporting. ThePrint – with exceptional reporters, columnists and editors – is doing just that.

Sustaining this needs support from wonderful readers like you.

Whether you live in India or overseas, you can take a paid subscription by clicking here.

Support Our Journalism

  • Tags

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular